Holen Sie sich die Stockscreener-App
0.00
100.00%
-76.01
Handel nachbörslich:
76.04
76.04
+
Schlusskurs vom Vortag:
$76.01
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$16.97B
Einnahmen:
$4.13B
Nettoeinkommen (Verlust:
$543.90M
KGV:
0.00
EPS:
2.41
Netto-Cashflow:
$957.20M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$76.07
Hologic Inc Stock (HOLX) Company Profile
Firmenname
Hologic Inc
Sektor
Telefon
(508) 263-2900
Adresse
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
0.00 | 16.97B | 4.13B | 543.90M | 957.20M | 2.41 |
ISRG
Intuitive Surgical Inc
|
403.18 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
143.92 | 39.67B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.12 | 31.54B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.30 | 30.39B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
191.26 | 27.36B | 5.54B | 1.52B | 1.74B | 10.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Herabstufung | Argus | Buy → Hold |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-21 | Herabstufung | BNP Paribas Exane | Outperform → Neutral |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-08-18 | Hochstufung | Argus | Hold → Buy |
| 2025-08-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-27 | Bestätigt | Needham | Hold |
| 2025-03-03 | Herabstufung | Argus | Buy → Hold |
| 2025-02-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | Herabstufung | Needham | Buy → Hold |
| 2024-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-12-10 | Bestätigt | Needham | Buy |
| 2024-10-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-27 | Eingeleitet | Stephens | Overweight |
| 2024-04-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-14 | Hochstufung | Needham | Hold → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-07-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-07-20 | Eingeleitet | UBS | Neutral |
| 2022-07-18 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-11-20 | Herabstufung | Needham | Buy → Hold |
| 2020-11-05 | Bestätigt | Needham | Buy |
| 2020-06-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-06-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | Bestätigt | Needham | Buy |
| 2020-04-30 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | Bestätigt | Needham | Buy |
| 2019-05-02 | Bestätigt | Needham | Buy |
| 2019-01-31 | Bestätigt | Needham | Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-09-13 | Herabstufung | BofA/Merrill | Buy → Neutral |
Alle ansehen
Hologic Inc Aktie (HOLX) Neueste Nachrichten
Hologic marks 40 years with new sustainability report, shares on NASDAQ in focus - Ad-hoc-news.de
The Panther Fusion SARS-CoV-2 Assay from Hologic Inc.fully automated PCR for high-throughput labs - AD HOC NEWS
Hologic Inc (HOLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Needles used to detect breast cancer in shortage from recall - MSN
Subtle hardware, big impactHologic Brevera in everyday breast biopsy - AD HOC NEWS
Hologic Stockweekly sector review and peer comparison - AD HOC NEWS
Quietly powerful in the lab, Hologic’s Aptima HPV assay pushes cervical screening forward - AD HOC NEWS
Le nouveau Rapport de durabilité d’Hologic célèbre 40 ans de réalisations - Eagle-Tribune
Hologic Inc (HOLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
How hospitals are managing Medline, Hologic product shortages - Modern Healthcare
Twin Securities, Inc.'s Hologic Inc(HOLX) Holding History - GuruFocus
Monongahela All Cap Value Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Hologic Inc (HOLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Hologic Inc (HOLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Hologic Inc (HOLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Hologic Inc (HOLX) Institutional Confidence - TradingKey
Hologic’s New Sustainability Report Marks 40 Years of Impact - Hologic
Needles Used to Detect Breast Cancer in Shortage From Recall - Bloomberg.com
Hologic wins patent case against Siemens Healthineers over mammo technology - DOTmed
Needles Used to Detect Breast Cancer in Shortage After Recall - Bloomberg.com
Hologic Inc (HOLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FDA warns breast biopsy needle shortage to continue into 2027 - MedTech Dive
Hologic Inc (HOLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Hologic Wins Patent Battle Against Siemens Healthineers, Orders Mammography System Recall - Medical Product Outsourcing
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology - TradingView
Quality Beyond Compliance: Malik Khan on Protecting Patients and Powering Performance - Hologic
Hologic Stock (US4364401012): Valuation and women's health strategy in focus after S&P 500 exit - AD HOC NEWS
Hologic Inc Stock (US4364401012): S&P 500 exit keeps women’s health specialist on U.S. investors� - AD HOC NEWS
Yakira Capital Management, Inc.'s Hologic Inc(HOLX) Holding History - GuruFocus
Hologic Stock (US4364401012): S&P 500 exit puts women’s health specialist back under the microscop - AD HOC NEWS
Hologic Stock (US4364401012): Valuation Metrics Under the Microscope - AD HOC NEWS
Siemens Hit With UPC Sales Ban Over Breast-Screening Tech - Law360
First Trust Merger Arbitrage Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Siemens ordered to recall mammography device across European countries - Life Sciences Intellectual Property Review
Life After Breast Cancer: Why Treatment Decisions Are Becoming More Personal - Hologic
· Analyst Forecast - MLQ.ai
T-Score & DXA: How Hologic Helped Define Bone Health - Hologic
LivaNova Appoints Anne Liddy as Chief Legal Officer - Business Wire
Hologic CEO Steve MacMillan to retire as go-private deal closes - Investing.com
BlackRock Event Driven Equity Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Newly Published Data Suggests AI’s Potential to Help Streamline Mammography Reviews While Maintaining High Effectiveness in Finding Cancer - Hologic
GABELLI & Co INVESTMENT ADVISERS, INC.'s Hologic Inc(HOLX) Holding History - GuruFocus
Hologic, Inc. (HOLX) Stock Analysis: Navigating Modest Growth And Strategic Stability - DirectorsTalk Interviews
Hologic's BCI test shows growing impact in endocrine therapy decisions - MSN
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions - BioSpace
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index - Business Wire
Hologic, Inc. (HOLX) Stock Analysis: Navigating Steady Growth In The Healthcare Sector - DirectorsTalk Interviews
OCONNOR, A Distinct Business Unit Of UBS ASSET MANAGEMENT AMERICAS (LLC) HOLX Holdings History - GuruFocus
Absolute Gestao de Investimentos Ltda.'s Hologic Inc(HOLX) Holding History - GuruFocus
The Official Home of the Women's Tennis Association | WTA Tennis - WTA Tennis
Hologic, Inc. (HOLX) Stock Analysis: Steady Growth With A Strong Focus On Women's Health - DirectorsTalk Interviews
Finanzdaten der Hologic Inc-Aktie (HOLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):